Second-line chemotherapy in malignant pleural mesothelioma (MPM)

H. G. Bischoff, C. Manegold, P. Drings (Heidelberg, Germany)

Source: Annual Congress 2002 - Mesothelioma and malignant pleural effusion
Session: Mesothelioma and malignant pleural effusion
Session type: Thematic Poster Session
Number: 1744
Disease area: Thoracic oncology

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
H. G. Bischoff, C. Manegold, P. Drings (Heidelberg, Germany). Second-line chemotherapy in malignant pleural mesothelioma (MPM). Eur Respir J 2002; 20: Suppl. 38, 1744

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Multimodal therapy in malignant pleural mesothelioma (MPM)
Source: Eur Respir J 2002; 20: Suppl. 38, 187s
Year: 2002

Chemotherapy for treatment of malignant pleural mesothelioma
Source: Eur Respir J 2004; 24: Suppl. 48, 526s
Year: 2004

Systemic therapy 1 in malignant pleural mesothelioma: chemotherapy
Source: ERS Online Course 2020: Calendar sheets in malignant pleural diseases
Year: 2020

Bevacizumab-targeted therapy for malignant pleural mesothelioma
Source: International Congress 2017 – Malignant pleural effusion management in 2017: a review of recent RCTs
Year: 2017


Polychemotherapy experience in pleural mesothelioma with or without pemetrexed
Source: Annual Congress 2009 - Pleural and mediastinal diseases
Year: 2009


Systemic treatment of malignant mesothelioma
Source: Eur Respir Mon; 2009: 44: 419–434
Year: 2009

Multimodality therapy for malignant pleural mesothelioma
Source: Eur Respir J 2004; 24: Suppl. 48, 526s
Year: 2004

Treatment of malignant pleural mesothelioma with caelyx: few responses but good survival
Source: Eur Respir J 2004; 24: Suppl. 48, 526s
Year: 2004

Is there any advantage of chemotherapy on survival of patients with diffuse malignant pleural mesothelioma?
Source: Eur Respir J 2003; 22: Suppl. 45, 29s
Year: 2003

Role of surgery and of radiotherapy in malignant pleural mesothelioma
Source: ERS Online Course 2020: Calendar sheets in malignant pleural diseases
Year: 2020


Efficacy of pleurodesis for malignant pleural effusions in breast cancer patients
Source: Eur Respir J 2011; 38: 1425-1430
Year: 2011



Three dimensional evaluation of chemotherapy response in malign pleural mesothelioma
Source: Eur Respir J 2007; 30: Suppl. 51, 754s
Year: 2007

Efficacy of EGFR-TKI for malignant pleural effusion in lung adenocarcinoma patients
Source: International Congress 2017 – Mesothelioma and malignant pleural disease
Year: 2017

Evaluation of response to chemotherapy for malignant pleural mesothelioma and suggestion of a new method
Source: Eur Respir J 2002; 20: Suppl. 38, 272s
Year: 2002

Systemic therapy 2 in malignant pleural mesothelioma: immuno- & targeted therapy
Source: ERS Online Course 2020: Calendar sheets in malignant pleural diseases
Year: 2020

Cisplatin/pemetrexed chemotherapy versus palliative care survival in malignant pleural mesothelioma
Source: International Congress 2018 – Clinical management of pleural malignancies, including mesothelioma
Year: 2018

Comparison between treatment with IL2, and IL2 in combination with chemotherapy in malignant pleural mesothelioma
Source: Annual Congress 2009 - Pleural and mediastinal diseases
Year: 2009


Efficacious pleurodesis with OK-432 and doxorubicin against malignant pleural effusions
Source: Eur Respir J 2004; 24: 263-266
Year: 2004



Hypotonic carboplatin pleurodesis for malignant pleural effusion of non-small cell lung cancer
Source: Eur Respir J 2002; 20: Suppl. 38, 273s
Year: 2002

Local (LICT) and systemic immunochemotherapy (SICT) after surgery in malignant pleural mesothelioma (MPM)
Source: Eur Respir J 2004; 24: Suppl. 48, 526s
Year: 2004